APA

Goldner G., Bombosch V., Geinitz H., Becker G., Wachter S., Glocker S., Zimmermann F., Wachter-Gerstner N., Schrott A., Bamberg M., Molls M., Feldmann H. & Pötter R. (20090715). Moderate risk-adapted dose escalation with three-dimensional conformal radiotherapy of localized prostate cancer from 70 to 74 Gy. First report on 5-year morbidity and biochemical control from a prospective Austrian-German multicenter phase II trial. : Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

Chicago

Goldner Gregor, Bombosch Valentin, Geinitz Hans, Becker Gerd, Wachter Stefan, Glocker Stefan, Zimmermann Frank, Wachter-Gerstner Natascha, Schrott Andrea, Bamberg Michael, Molls Michael, Feldmann Horst and Pötter Richard. 20090715. Moderate risk-adapted dose escalation with three-dimensional conformal radiotherapy of localized prostate cancer from 70 to 74 Gy. First report on 5-year morbidity and biochemical control from a prospective Austrian-German multicenter phase II trial. : Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

Harvard

Goldner G., Bombosch V., Geinitz H., Becker G., Wachter S., Glocker S., Zimmermann F., Wachter-Gerstner N., Schrott A., Bamberg M., Molls M., Feldmann H. and Pötter R. (20090715). Moderate risk-adapted dose escalation with three-dimensional conformal radiotherapy of localized prostate cancer from 70 to 74 Gy. First report on 5-year morbidity and biochemical control from a prospective Austrian-German multicenter phase II trial. : Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

MLA

Goldner Gregor, Bombosch Valentin, Geinitz Hans, Becker Gerd, Wachter Stefan, Glocker Stefan, Zimmermann Frank, Wachter-Gerstner Natascha, Schrott Andrea, Bamberg Michael, Molls Michael, Feldmann Horst and Pötter Richard. Moderate risk-adapted dose escalation with three-dimensional conformal radiotherapy of localized prostate cancer from 70 to 74 Gy. First report on 5-year morbidity and biochemical control from a prospective Austrian-German multicenter phase II trial. : Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]. 20090715.